Key facts
- Limula’s last known valuation is $15.7M.
- It has raised $12.0M; the latest was Seed Round ($5.7M) in May 2024.
- Notable investors include MassChallenge, MedTech Innovator, Venture Kick, Ecole Polytechnique Federale de Lausanne, Innosuisse — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Limula
- ·The full record, as it builds
Funding rounds
No funding rounds for Limula are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Limula
Developer of automated cell therapy manufacturing platforms designed for scalable production. The company's platform integrates bioreactor and centrifuge functionalities into a single device, automating complex cell processing steps without human intervention, featuring in-situ centrifugation, modular design, scalability, versatility for various cell types, and an intuitive user interface, enabling biotech and pharmaceutical companies to transition from open, manual methods to closed, automated processes, improving efficiency and accessibility in cell and gene therapy manufacturing.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2018
- Employees
- 20
- Website
- limula.ch/
- Ownership
- Privately Held (backing)
Limula doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Limula shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Limula in its N-PORT filings yet. We sweep new filings monthly.